Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
An announcement from 4D Molecular Therapeutics ( (FDMT) ) is now available.
On December 31, 2025, Fariborz Kamal, Ph.D., resigned as President and Chief Operating Officer of 4D Molecular Therapeutics to pursue other opportunities, while transitioning to a part-time role as Chief Technical Advisor; the company stated his departure was not due to any disagreement over operations, outlook, or governance. Effective January 1, 2026, current Chief Executive Officer David Kirn, M.D., assumed the additional role of President, consolidating top leadership, and on January 5, 2026, the board appointed veteran biopharma executive Glenn Sblendorio as a Class I director and committee member, granting him standard stock options and cash retainers, moves that collectively signal management continuity and strengthened board expertise in finance, operations, and therapeutic development for the company and its stakeholders.
The most recent analyst rating on (FDMT) stock is a Hold with a $7.00 price target. To see the full list of analyst forecasts on 4D Molecular Therapeutics stock, see the FDMT Stock Forecast page.
Spark’s Take on FDMT Stock
According to Spark, TipRanks’ AI Analyst, FDMT is a Neutral.
The score is held down primarily by weak financial performance (minimal revenue, large and widening losses, and heavy cash burn) and bearish technical trend signals. Offsetting this, recent corporate events are constructive—particularly the Otsuka partnership and positive interim trial results—while valuation remains hard to justify given ongoing losses and no dividend support.
To see Spark’s full report on FDMT stock, click here.
More about 4D Molecular Therapeutics
4D Molecular Therapeutics operates in the biopharmaceutical sector, focusing on the development of gene therapy and related therapeutics, with a market focus on innovative treatments supported by advanced science and technology leadership.
Average Trading Volume: 1,003,973
Technical Sentiment Signal: Sell
Current Market Cap: $417.1M
Learn more about FDMT stock on TipRanks’ Stock Analysis page.